674 related articles for article (PubMed ID: 28734831)
1. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
3. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
5. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
[TBL] [Abstract][Full Text] [Related]
6. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
7. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
[TBL] [Abstract][Full Text] [Related]
8. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
10. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
[TBL] [Abstract][Full Text] [Related]
11. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients.
Kim TY; Jeong WK; Sohn JH; Kim J; Kim MY; Kim Y
Liver Int; 2015 Nov; 35(11):2416-24. PubMed ID: 25875718
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
16. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
[TBL] [Abstract][Full Text] [Related]
17. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
[TBL] [Abstract][Full Text] [Related]
18. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study.
Jansen C; Bogs C; Verlinden W; Thiele M; Möller P; Görtzen J; Lehmann J; Vanwolleghem T; Vonghia L; Praktiknjo M; Chang J; Krag A; Strassburg CP; Francque S; Trebicka J
Liver Int; 2017 Mar; 37(3):396-405. PubMed ID: 27569696
[TBL] [Abstract][Full Text] [Related]
19. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]